title: Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.
abstract: OBJECTIVE
  To compare the incidence of hypoglycemic events in patients exposed to gatifloxacin or levofloxacin, and to measure the odds of experiencing a hypoglycemic event after receiving gatifloxacin versus levofloxacin while adjusting for confounders.
  
  
  METHODS
  Nested case-control study within a historical cohort.
  
  
  METHODS
  A tertiary care, 730-bed, teaching hospital in central Illinois.
  
  
  METHODS
  Seven thousand two hundred eighty-seven hospitalized patients who received gatifloxacin or levofloxacin therapy.
  
  
  RESULTS
  A total of 113 patients (case patients) had blood glucose levels below 51 mg/dl; 113 control patients, matched for age and sex, had no hypoglycemia. Matched conditional logistic regression models adjusted the odds of having hypoglycemia for significant covariates. The 12-month incidence of hypoglycemia was 11/1000 patients after levofloxacin administration and 21/1000 patients after gatifloxacin (absolute risk increase 10/1000 patients, 95% confidence interval [CI] 4-16/1000). Renal failure, sepsis syndrome, and concomitant hypoglycemic drug therapy significantly predicted hypoglycemia. After adjustment for significant predictors, the odds of having hypoglycemia were 2.81 (95% CI 1.02-7.70) times higher after gatifloxacin than levofloxacin therapy.
  
  
  CONCLUSIONS
  Among inpatients, the incidence of hypoglycemic events is greater after treatment with gatifloxacin than levofloxacin. The odds of experiencing hypoglycemic events are greater with gatifloxacin even after adjusting for other hypoglycemia risk factors, such as concomitant hypoglycemic drugs, renal failure, and sepsis syndrome.
authors.affiliation: Department of Medicine, College of Medicine, University of Illinois, Peoria, IL 61637, USA.
authors.forename: James F
authors.initials: JF
authors.lastname: Graumlich
authors.forename: Saba
authors.initials: S
authors.lastname: Habis
authors.forename: Rosario R
authors.initials: RR
authors.lastname: Avelino
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Salverson
authors.forename: Madhavi
authors.initials: M
authors.lastname: Gaddamanugu
authors.forename: Kiranmai
authors.initials: K
authors.lastname: Jamma
authors.forename: Jean C
authors.initials: JC
authors.lastname: Aldag
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001786:Blood Glucose / Q000032:analysis; D016022:Case-Control Studies; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects*; D000077734:Gatifloxacin; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D000890:Anti-Infective Agents; D001786:Blood Glucose; D024841:Fluoroquinolones; D064704:Levofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin